[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tanta University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":609},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,212,0,25,[9,45,73,93,112,139,159,178,206,229,264,297,318,341,362,384,406,429,459,480,501,524,543,567,590],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100652292","phase-2-treatment-of-ckd-patients-with-hcv-100652292",false,"NCT07770984","Treatment of CKD Patients With HCV","Clinical Study Evaluating the Optimal Drug Therapy in Chronic Kidney Disease Patients With HCV","HCV\u002FCKD","Inclusion Criteria:\n\n1. Both male and female.\n2. Adults more than 18 years.\n3. Patients with CKD different stages stable on treatment with or without HD.\n4. HD Patients should be stable for at least 6 months under regular hemodialysis.\n5. Clinically stable condition as outpatients.\n6. Patients with HCV infections (serum positive for HCV GT4 with HCV RNA\\>1000 IU\u002Fml by PCR).\n7. White blood cells count more than 2500\u002Fmm3.\n8. Platelet count more than 7500\u002Fmm3.\n\nExclusion Criteria:\n\n1. Confirmed pregnancy.\n2. HCV-HIV co infection.\n3. HBV-HCV co infection.\n4. Unstable CKD patients.\n5. Patients who are recently stabilized on HD (less than 6 months).\n6. Patients on peritoneal dialysis.\n7. For patients without cirrhosis, Patients will be excluded if ALT or AST more than five times the upper limit of normal.\n8. For patients with cirrhosis, Patients will be excluded if ALT or AST are higher than seven times the upper limit of normal.","ALL","18 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","The goal of this clinical trial is to evaluate the optimal drug therapy of HCV in CKD Patients different stages with or without compensated cirrhosis. The main questions it aims to answer are:\n\noutcome measure 1: Efficacy of the treatment by the assessment of sustained virological response (SVR12) following 12 weeks after the last dose HCV RNA drop to undetectable levels.\n\noutcome measure 2: Safety of the treatment by comparing the biochemical parameters before and after treatment.\n\nIf there is a comparison group: Researchers will compare biochemical parameters of the participants before and after treatment to see if there is any decline in the general health.\n\nParticipants will be divided to two groups according to their kidney status depending on their GFR, Group 1: 25 CKD Patients with eGFR more than 30ml\u002Fmin with HCV infection and will receive Sofosbuvir and Daclatasvir regimen for 12 weeks, Group 2: 25 CKD Patients with eGFR less than 30ml\u002Fmin with HCV infection and will receive Paritaprevir, Ombitasvir, Ritonavir and Ribavirin for 12 weeks.",[29],"HCV Infection ( Genotype 4) in CKD Patients",[31],"CKD\u002FHCV","NOT_YET_RECRUITING","2026-08-18",{"date":35,"type":36},"2026-08-20","ACTUAL",{"date":38,"type":22},"2026-09-15",{"date":40,"type":22},"2027-05-15",{"name":42,"class":43},"Tanta University","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100652717","intrathecal-morphine-versus-intrathecal-dexmedetomidine-compared-to-placebo-for-postoperative-pain-relief-after-spine-fixation-surgeries-100652717","NCT07777627","Intrathecal Morphine Versus Intrathecal Dexmedetomidine Compared to Placebo for Postoperative Pain Relief After Spine Fixation Surgeries","Intrathecal Morphine Versus Intrathecal Dexmedetomidine Compared to Placebo for Postoperative Pain Relief After Spine Fixation Surgeries: A Randomized Double-Blinded Study","Inclusion Criteria:\n\n* Aged between 21 and 60 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) Physical Status I or II.\n* Scheduled for elective lumbar spine fixation surgery under general anesthesia.\n\nExclusion Criteria:\n\n* Patients' refusal.\n* Decompensated hepatic or renal or cardiac disease.\n* Coagulation disorder.\n* Pregnancy and lactation.\n* Body mass index above 30 kg\u002Fm2.\n* Severe pulmonary disorders.\n* Patients on opioid, alcohol or allergy to any of the study drugs.","21 Years","60 Years",{"count":55,"type":22},90,[57],"NA","This study aims to compare the efficacy of intrathecal morphine and intrathecal dexmedetomidine in reducing pain following lumbar spine fixation surgeries.",[60,61,62,63,64],"Intrathecal Morphine","Intrathecal Dexmedetomidine","Placebo","Postoperative Pain","Spine Fixation Surgeries","RECRUITING","2026-08-17",{"date":35,"type":36},{"date":69,"type":36},"2026-07-01",{"date":71,"type":22},"2028-07-01",{"name":42,"class":43},{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":53,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100639485","phase-2-allopurinol-in-depression-100639485","NCT07574060","Allopurinol in Depression","Allopurinol Adjuvant Therapy in Patients With Major Depressive Disorder","Inclusion Criteria:\n\nPatients aged greater than 18 years old. Patients with a HAM-D score of at least 10 with item 1, depressed mood, scoring 2 or greater, are eligible.\n\nExclusion Criteria:\n\nPatients with bipolar I or bipolar II disorder Patients with eating disorders Pregnant women or women not using medically accepted means of birth control Cardiovascular disorders Severe renal impairment",{"count":81,"type":22},70,[25,26],"Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients.",[85],"Depression","2026-08-16",{"date":33,"type":36},{"date":89,"type":36},"2026-05-20",{"date":91,"type":22},"2027-05-20",{"name":42,"class":43},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":44},"100582259","phase-3-evaluating-the-safety-and-efficacy-of-duloxetine-in-the-prevention-of-post-endoscopic-retrograde-cholangiopancreatography-pancreatitis-100582259","NCT06860984","Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis","Inclusion Criteria:\n\n* Age more than 18 years old.\n* Gender: Males and Females\n* Patients with suitable indications for ERCP due to suspected pancreato-biliary disorders.\n* Blood amylase and lipase levels before ERCP are within the normal limits\n\nExclusion Criteria:\n\n* Uncontrolled diabetes mellitus (DM)\n* Severe bleeding tendency\n* Impaired renal function (serum creatinine \\> 2 mg\u002FdL), (creatinine clearance \\\u003C30 ml\u002Fmin)\n* Patients with severe heart disease.\n* Subjects who underwent prior biliary or pancreatic sphincterotomy or dilatation or stenting of either duct.\n* Currently pregnant or nursing\n* Admission due to established pancreatitis before ECRP\n* Unwillingness to undergo ERCP.","65 Years",{"count":101,"type":22},44,[26],"Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.",[105],"Biliary Disease",{"date":33,"type":36},{"date":108,"type":36},"2025-03-10",{"date":110,"type":22},"2027-07-10",{"name":42,"class":43},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":44},"100651451","evaluation-the-accuracy-of-immediate-implant-placement-using-socketfit-static-surgical-guide-versus-conventional-static-surgical-guide-in-anterior-esthetic-zone-100651451","NCT07760974","Evaluation the Accuracy of Immediate Implant Placement Using SocketFit Static Surgical Guide Versus Conventional Static Surgical Guide in Anterior Esthetic Zone","SocketFit","Inclusion Criteria:\n\n* Patients in good health with absence of any relevant medical condition that contraindicates dental implant placement e.g. blood coagulation disorder.\n* Optimal compliance is evidenced by no missed treatment appointments and a positive attitude toward oral hygiene.\n* Extraction socket type I according to Ellian et al criteria with adequate native\u002Fapical bone to achieve primary implant stability and intact buccal plate of bone.\n* Thick mucosal phenotype.\n* Probing depth ≤ 3 mm at mid-buccal aspect of failing tooth.\n* Age ranged from 18- 35 years old of both genders.\n\nExclusion Criteria:\n\n* Patients subjected to irradiation in the head and neck area.\n* Bisphosphonate therapy.\n* Females who are pregnant or trying to conceive, and nursing mothers.\n* Smokers and uncontrolled diabetic patients.","35 Years",{"count":121,"type":22},26,[57],"This study compares two types of surgical guides used during immediate dental implant placement in the upper front teeth. One guide is a conventional static surgical guide, while the other is a modified SocketFit static surgical guide designed to improve stability after tooth extraction. The purpose of the study is to determine whether the SocketFit guide improves the accuracy of implant placement.The findings may help improve the precision and predictability of immediate dental implant treatment in the anterior esthetic zone.",[125,126],"Conventional Static Surgical Guide","SocketFit Static Surgical Guide",[128,129,130],"immediate implant placement","Superimposition","Accuracy of implant placement","2026-08-11",{"date":133,"type":36},"2026-08-13",{"date":135,"type":36},"2026-08-01",{"date":137,"type":22},"2027-07",{"name":42,"class":43},{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":44},"100645410","detection-of-early-scapular-dyskinesis-100645410","NCT07681999","Detection of Early Scapular Dyskinesis","Detection of Early Inflammatory Versus Early Mechanical Scapular Dyskinesis","Inclusion Criteria:\n\n* treatment-naïve patients with ankylosing spondylitis (AS), who fulfilled the Assessment of Spondylarthritis Society (ASAS) criteria for axial spondyloarthritis (ax-SpA)\n* Inclusion criterion for the second group (non-AS individuals) was patients complaining of discomfort upon activity.\n\nExclusion Criteria:\n\n* The exclusion criteria of the first group included:\n\n  1. patients with a history of local trauma\n  2. and\u002For surgical intervention,\n  3. neuromascular deficits,\n  4. chronic chest disease and\n  5. other inflammatory autoimmune\u002Frheumatologic conditions.\n* Exclusion criteria for the second group were:\n\n  1. a history of AS or\n  2. other systemic autoimmune\u002F rheumatologic disease.",{"count":147,"type":22},100,"OBSERVATIONAL","This study is a prospective blind contrast between periscapular muscle thickness measured with MSUS in patients with early AS in comparison to patients with mechanical dyskinesis and to correlate it with EMG findings.",[151],"Scapular Dyskinesis","2026-08-09",{"date":131,"type":36},{"date":155,"type":36},"2026-06-19",{"date":157,"type":22},"2026-08",{"name":42,"class":43},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":44},"100644127","cryoneurolysis-versus-radiofrequency-in-knee-osteoarthritis-100644127","NCT07664371","Cryoneurolysis Versus Radiofrequency in Knee Osteoarthritis","Cryoneurolysis Versus Radiofrequency in Knee Osteoarthritis: A Randomised Controlled Trial","Inclusion Criteria:\n\nAdults with a clinical diagnosis of refractory knee OA who suffered from refractory knee pain (patients who had failed conservative medical and physical therapy for 6 months .\n\nExclusion Criteria:\n\n1. Patients with OA show improvement in pain after conservative medical and physical therapy.\n2. Patients evaluated by an orthopedic surgeon and deemed to be surgical candidates due to knee pathologies other than OA.\n3. Patients with allergies to local anesthetics.\n4. patients on anticoagulation therapy, who were not permitted to stop anticoagulation.\n5. Patients with knee tumors.\n6. Patients with acute infections.\n7. Patients with implanted cardiac devices.\n8. Pregnant patients.",{"count":167,"type":22},30,[57],"The project will evaluate the effectiveness of Cryoneurolysis versus radiofrequency procedures in adult patients who are resistant to traditional treatment for knee pain. They are a drug-free pain management procedure.",[171],"Knee Osteoarthritis",{"date":131,"type":36},{"date":174,"type":36},"2026-06-10",{"date":176,"type":22},"2026-11",{"name":42,"class":43},{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":185,"minAge":19,"maxAge":99,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":188,"briefSummary":189,"conditions":190,"keywords":193,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},"100641608","subtransverse-interligamentary-block-versus-paravertebral-block-for-quality-of-recovery-after-mastectomy-100641608","NCT07647367","Subtransverse Interligamentary Block Versus Paravertebral Block for Quality of Recovery After Mastectomy","Ultrasound-Guided Subtransverse Interligamentary Plane Block Versus Thoracic Paravertebral Block for Quality of Recovery After Modified Radical Mastectomy: A Randomized Non-Inferiority Trial","Inclusion Criteria:\n\n* Adult female patients aged 18 to 65 years with American Society of Anesthesiologists (ASA) Physical Status I - III, who were scheduled for unilateral MRM surgery under general anesthesia and able to understand and complete the QoR-15 questionnaire\n\nExclusion Criteria:\n\n* • Patients declined to participate in the trial.\n\n  * History of allergy to the used local anesthetic (LA) drugs.\n  * Patients with cutaneous lesions at the needle entry point.\n  * Coagulopathy or current anticoagulant therapy contraindicating regional block.\n  * Patients with severe hepatic, renal, cardiac, or respiratory disease.\n  * Psychiatric or cognitive disorder interfering with QoR-15 assessment\n  * Chronic opioid use or chronic pain syndrome.\n  * Failed block.\n  * Morbid obesity (body mass index \\>40 kg\u002Fm2)\n  * Intraoperative major complications requiring postoperative ICU admission.\n  * Pregnancy","FEMALE",{"count":187,"type":22},60,[57],"This prospective randomized controlled double blinded non-inferiority study will be carried out in Tanta University Hospitals for duration of 6 months from June 2026 to December 2026 on 60 female patients scheduled for unilatral modified radical mastectomy under general anesthesia.",[191,192],"Quality of Recovery (QoR-15)","Modified Radical Mastectomy",[194,195,196],"subtransverse interligamentary plane block","modified radical mastectomy","quality of recovery","2026-08-02",{"date":199,"type":36},"2026-08-04",{"date":201,"type":36},"2026-06-20",{"date":203,"type":22},"2027-01",{"name":42,"class":43},2,{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":226,"leadSponsor":228,"locationsCount":44},"100650256","phase-2-clinical-study-comparing-diosmin-vs-rebamipide-as-adjuvant-therapies-vs-conventional-therapy-in-patients-with-rheumatoid-arthritis-100650256","NCT07745426","Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis","Inclusion Criteria:\n\n* Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR). i.e.,28 joints disease activity score (DAS-28) \\>2.6.\n* Both sexes.\n* Age ranges between 18 and 70 years old.\n* Patients receiving conventional DMARDs\n\nExclusion Criteria:\n\n* Pregnant and lactating females.\n* Patients receiving biological DMARDs or targeted synthetic DMARDs.\n* Patients with renal and hepatic dysfunction.\n* Patients with other inflammatory\u002Fautoimmune diseases, active infection, or malignancies.\n* Patients with bleeding disorders, receiving warfarin or other anticoagulants.\n* Patients receiving antioxidants.\n* Patients with hypersensitivity to study medications.","70 Years",{"count":214,"type":22},66,[25],"This study will be a randomized controlled parallel study that will be conducted on 66 patients with active rheumatoid arthritis who will be diagnosed with RA according to American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR, 2010). The patients will be recruited from Outpatient Clinic of Rheumatology, Physical Medicine, Rheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt. The study duration will be 3 months. The patients will be randomized into three groups:\n\n\\- Group 1 (control group): will include 22 patients who will receive the conventional therapy for RA for 3 months.\n\n\\- Group 2 (diosmin group): will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months.\n\n\\- Group 3 (rebamipide group): will include 22 patients who will receive the conventional therapy for RA plus 100 mg rebamipide three times daily for 3 months.",[218],"Rheumatoid Arthritis (RA)",[220,221,222],"rheumatoid arthritis","diosmin","rebamipide","2026-07-29",{"date":199,"type":36},{"date":135,"type":22},{"date":227,"type":22},"2027-08-01",{"name":42,"class":43},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":236,"sex":18,"minAge":237,"maxAge":53,"enrollmentInfo":238,"targetDuration":4,"studyType":23,"phases":240,"briefSummary":241,"conditions":242,"keywords":247,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":44},"100649886","effect-of-scanning-techniques-on-accuracy-of-mandibular-fixed-detachable-prostheses-100649886","NCT07740265","Effect of Scanning Techniques on Accuracy of Mandibular Fixed Detachable Prostheses","Influence of Three Different Scanning Techniques on Scanning Accuracy for Mandibular Fixed Detachable Prosthesis (A Cross Over Study).","Inclusion Criteria:\n\n1. Completely edentulous patients with age between 40-60 years.\n2. Adequate bone height to fulfill the criteria for implant placement.\n3. Patients should have a class I Angle's classification.\n\nExclusion Criteria:\n\n1-. Insufficient vertical inter-arch space to accommodate the restorative components.\n\n2\\. Presence of psychiatric or neurological conditions. 3. Any systemic diseases that may affect implant bone osteointegration.",true,"40 Years",{"count":239,"type":22},7,[57],"This crossover clinical study aims to evaluate the influence of three different intraoral scanning techniques on the scanning accuracy and passive fit of mandibular implant-supported fixed detachable prostheses in completely edentulous patients. Each participant will undergo digital implant scanning using three methods: splinted scan bodies, horizontal non-calibrated scan bodies (IO Connect), and auxiliary geometric devices.",[243,244,245,246],"Dental Prosthesis, Implant-Supported","Prosthodontics","Complete Edentulism","Full Arch Implant Rehabilitation",[248,249,250,251,252,253,254,255],"Intraoral Scanner","Digital impression","Passive fit","Auxiliary Geometric Device","Fixed Detachable Prosthesis","Implant Scan Body","Full-arch implant","horizontal scan body","2026-07-28",{"date":258,"type":36},"2026-07-31",{"date":260,"type":22},"2026-08-08",{"date":262,"type":22},"2027-07-01",{"name":42,"class":43},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":236,"sex":18,"minAge":271,"maxAge":212,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":275,"conditions":276,"keywords":280,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":294,"leadSponsor":296,"locationsCount":44},"100649798","3d-printing-orientation-and-film-thickness-for-maxillary-complete-dentures-100649798","NCT07740278","3D Printing Orientation and Film Thickness for Maxillary Complete Dentures","Clinical and Laboratory Assessment of 3D Printing Orientation and Film Thickness on the Accuracy and Patient Satisfaction of Maxillary Complete Dentures","Inclusion Criteria:\n\n1. Completely edentulous patients with good local and systemic health.\n2. Patients age ranging from 50 to 70 years old.\n3. Patients with adequate inter-arch space.\n4. Patients with good neuromuscular control.\n\nExclusion Criteria:\n\n1. Patients with any oral diseases which may affect denture construction\n2. Patients with oral parafunctional habits.\n3. Patients with tempro-mandibular disorders","50 Years",{"count":273,"type":22},15,[57],"This randomized crossover clinical trial aims to evaluate the effect of different three-dimensional (3D) printing orientations and layer thicknesses on the trueness, dimensional accuracy, and patient satisfaction of maxillary complete dentures in completely edentulous patients. Each participant will receive two maxillary 3D-printed complete dentures fabricated using the same printing orientation (0°, 45°, or 90°) with two different layer thicknesses (50 μm and 100 μm) in a crossover sequence. The study will compare the influence of these printing parameters on denture accuracy and patient-reported outcomes to identify the optimal 3D printing settings for complete denture fabrication.",[245,277,244,278,279],"Maxillary Complete Denture Rehabilitation","3d Printing","Digital Denture",[281,282,283,284,285,286,287,288,289,290,291],"Digital dentistry","Patient satisfaction","Dimensional accuracy","Denture trueness","Layer thickness","Build orientation","CAD\u002FCAM dentures","Additive manufacturing","Three-dimensional printing","Maxillary complete denture","Complete edentulism",{"date":258,"type":36},{"date":260,"type":22},{"date":295,"type":22},"2027-03-01",{"name":42,"class":43},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":315,"leadSponsor":317,"locationsCount":44},"100649422","midpoint-transverse-process-to-pleura-mtp-block-vs-erector-spinae-plane-esp-block-for-acute-herpes-zoster-hz-pain-100649422","NCT07732556","Midpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) Pain","Comparison Between Midpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) Pain","Inclusion Criteria:\n\n* Age 21-60 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status I-II.\n* Acute thoracic herpes zoster within 30 days of rash onset.\n* Moderate to severe pain \\[numeric rating scale (NRS)≥4\\].\n\nExclusion Criteria:\n\n* Refusal to participate.\n* Coagulopathy or anticoagulant therapy.\n* Infection at puncture site.\n* Allergy to study drugs.\n* Severe psychiatric illness or inability to assess pain.\n* Previous thoracic surgery deformity.\n* Uncontrolled Diabetic patient.\n* Chronic diseases as renal, hepatic, malignancy.\n* Patients with chronic disease need analgesia.\n* Patients are coming for more than 3 months (after healing of rash).",{"count":55,"type":22},[57],"The aim of this study is to compare the analgesic efficacy and safety of ultrasound-guided midpoint transverse process block versus ultrasound-guided erector spinae plane block in patients suffering from thoracic herpes zoster pain.",[308,309,310,311],"Midpoint Transverse Process to Pleura Block","Erector Spinae Plane Block","Acute Herpes Zoster","Pain","2026-07-23",{"date":223,"type":36},{"date":69,"type":36},{"date":316,"type":22},"2027-06-01",{"name":42,"class":43},{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":340,"locationsCount":205},"100623830","dysphagia-in-rheumatoid-arthritis-100623830","NCT07401732","Dysphagia in Rheumatoid Arthritis","Prediction of Dysphagia and Its Possible Causes in Rheumatoid Arthritis: A Cross-Sectional Study","Inclusion Criteria:\n\n* Patients with Rheumatoid arthritis defined by the American College of Rheumatology\u002FEuropean League Against Rheumatism collaborative initiative (ACR\u002FEULAR) 2010 classification criteria.\n* Patients aged above 18 years old, well-orientated, and cooperative.\n\nExclusion Criteria:\n\n* concomitant thyroid dysfunction.\n* concomitant hypovitaminosis D.\n* concomitant cancer diagnosis, pregnancy.\n* jaw-related traumas, teeth, and gum diseases.\n* other rheumatologic conditions\n* other comorbidities.\n* other causes of TMJ arthritis, patients with TMJ, palatal or tongue congenital abnormalities, and patients who underwent TMJ injections in the last six months.\n* Patients with any language disorders or intellectually handicapped (as certain questions depend on the patient's ability to comprehend and express their emotions regarding their issue) and patients with anatomical anomalies impeding the functionality of flexible nasofibroscopy.\n* Any apparent causes of dysphagia other than RA.",{"count":167,"type":22},"The primary goal of this cross-sectional study is to assess risk factors\u002Fpredictors for dysphagia in RA.\n\nThe secondary goals include demonstrating whether flexible fiberoptic pharyngolaryngoscopy can detect joint-affection-induced dysphagia in patients with rheumatoid arthritis (RA) and whether both oropharyngeal and esophageal dysphagia are present among these patients.\n\nThe main questions it aims to answer are\n\n* What are the predictors that are associated with dysphagia via flexible fiberoptic pharyngolaryngoscopy in rheumatoid arthritis patients?\n* Whether flexible fiberoptic pharyngolaryngoscopy can detect joint-affection-induced dysphagia in patients with RA?\n* Whether both oropharyngeal and esophageal dysphagia are present in patients with RA?",[328],"Rheumatoid Arthritis (RA",[330,331,332,333],"Flexible Endoscopic Evaluations of Swallowing","Temporomandibular joint","Deglutition disorders","cricoarytenoid","2026-07-19",{"date":336,"type":36},"2026-07-21",{"date":338,"type":36},"2026-02-07",{"date":157,"type":22},{"name":42,"class":43},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":18,"minAge":349,"maxAge":237,"enrollmentInfo":350,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":359,"leadSponsor":361,"locationsCount":44},"100648365","removal-of-intracanal-medicaments-by-different-techniques-using-cone-beam-computed-tomography-analysis-100648365","NCT07719985","Removal of Intracanal Medicaments by Different Techniques Using Cone Beam Computed Tomography Analysis","\"Removal of Intracanal Medicament by Different Techniques: (Cone Beam Computed Tomography Analysis) (Clinical Study)\"","Ca(OH)2 - CBCT","Inclusion Criteria:\n\n1. Restorable mature non-vital single canal anterior tooth with or without signs of periapical pathosis.\n2. Teeth without anatomical variations\n3. Medically free patients\n\nExclusion Criteria:\n\n1. Non-restorable tooth\n2. Retreatment cases\n3. Teeth with root fractures\n4. Teeth with root resorption","20 Years",{"count":167,"type":22},[57],"the goal of this study is to evaluate the efficency of different activation techniques in removal of intracanal medication using cone beam computed tomography analysis",[354],"Removal of Intracanal Medication","2026-07-17",{"date":357,"type":36},"2026-07-22",{"date":157,"type":22},{"date":360,"type":22},"2027-03",{"name":42,"class":43},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":370,"briefSummary":371,"conditions":372,"keywords":374,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":44},"100645430","phase-2-clinical-study-to-evaluate-the-efficacy-of-febuxostat-in-the-treatment-of-conservatively-managed-intracranial-hemorrhage-patients-100645430","NCT07701512","Clinical Study to Evaluate the Efficacy of Febuxostat in the Treatment of Conservatively Managed Intracranial Hemorrhage Patients","Inclusion Criteria:\n\n* • Age ≥ 18 years old.\n\n  * Diagnosed with intracranial hemorrhage confirmed by CT scan.\n  * Managed conservatively regarding clinical guidelines.\n  * Able to provide informed consent or have a legal representative provide consent.\n\nExclusion Criteria:\n\n* • Patients with a history of previous brain surgery or significant neurological disorders.\n\n  * Severe comorbidities (e.g., uncontrolled diabetes, severe cardiac disease).\n  * Allergy or contraindication to febuxostat.\n  * Pregnant or breastfeeding women.\n  * Patients requiring surgical intervention for hematoma evacuation.\n  * Renal impairment with SCr \\> 4\n  * Liver impairment with INR \\> 5\n  * Significant deterioration ( GCS \\\u003C 8 )",{"count":369,"type":22},46,[25],"To assess the effect of Febuxostat on clinical outcomes and biomarkers of oxidative stress and inflammation in patients with conservatively managed intracranial hemorrhage.",[373],"Intracranial Hemorrhage",[375],"Intracranial hemorrhage","2026-07-14",{"date":378,"type":36},"2026-07-15",{"date":380,"type":36},"2025-11-20",{"date":382,"type":22},"2027-01-30",{"name":42,"class":43},{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":18,"minAge":391,"maxAge":19,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":44},"100647296","laparoscopic-management-of-gastroesophageal-reflux-disease-in-children-100647296","NCT07708220","Laparoscopic Management of Gastroesophageal Reflux Disease in Children","the Effect of the Laparoscopic Management of Gastro Esophageal Reflux on Gastric Emptying in Pediatric Age Group","Inclusion Criteria:\n\n* all children with GERD above the age of 24 months until 18 years\n\nExclusion Criteria:\n\n* previous antireflux surgery\n* previous exploration\n* Esophageal atresia congenital diaphragmatic hernia omphalocele major","24 Months",{"count":393,"type":22},36,[57],"gastric functions especially gastric emptying is still debatable after anti reflux surgery in children. this study aims to predict the best procedure associated with good gastric emptying time and gastric functions following anti reflux procedure when compared two procedures, Nissen fundoplication vs Hil snow fundoplication in multicenter pediatric surgery tertiary hospitals.",[397],"Gastric Function Disorder","2026-07-12",{"date":400,"type":36},"2026-07-16",{"date":402,"type":36},"2025-03-01",{"date":404,"type":22},"2026-10-01",{"name":42,"class":43},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":23,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":44},"100647492","airway-occlusion-pressure-p01-guided-pressure-support-ventilation-versus-conventional-management-in-weaning-window-patients-100647492","NCT07709182","Airway Occlusion Pressure (P0.1) Guided Pressure Support Ventilation Versus Conventional Management in Weaning Window Patients","Airway Occlusion Pressure (P0.1) Guided Pressure Support Ventilation Versus Conventional Management in Weaning Window Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Mechanically ventilated adult patients ≥ 21 years.\n* Patients on pressure support ventilation for at least 24 hours and clinically determined to be in the weaning window (transition between assisted ventilation and spontaneous ventilation) with improving respiratory status.\n* Hemodynamically stable \\[mean arterial pressure (MAP) ≥60 mmHg\\].\n* All patients will be required to have light sedation with a Richmond Agitation-Sedation Scale (RASS) score between -1 and 0 to allow reliable assessment of respiratory drive.\n\nExclusion Criteria:\n\n* Patients with neuromuscular disorders affecting respiratory drive\n* Glasgow Coma Scale (GCS) score below 8\n* Cervical spinal cord injury\n* Receipt of neuromuscular blockers within the previous 24 hours\n* Morbid obesity resulting in unreliable respiratory mechanics\n* Pregnancy\n* Deep sedation defined as RASS ≤ -2\n* Hemodynamic instability requiring escalating vasopressor support.",{"count":414,"type":22},80,[57],"This study aims to determine whether Airway Occlusion Pressure (P0.1) Guided Pressure Support Ventilation is superior to conventional management for patients in weaning windows.",[418,419,420,421],"Airway Occlusion Pressure","Pressure Support Ventilation","Conventional Management","Weaning Window Patients","2026-07-11",{"date":400,"type":36},{"date":425,"type":36},"2026-02-01",{"date":427,"type":22},"2028-01-01",{"name":42,"class":43},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":437,"maxAge":19,"enrollmentInfo":438,"targetDuration":4,"studyType":23,"phases":439,"briefSummary":440,"conditions":441,"keywords":445,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":44},"100646603","standard-versus-flexible-and-navigable-suction-ureteral-access-sheath-in-pediatric-flexible-ureterorenoscopy-for-renal-stones--2-cm-100646603","NCT07689565","Standard Versus Flexible and Navigable Suction Ureteral Access Sheath in Pediatric Flexible Ureterorenoscopy for Renal Stones \u003C 2 cm","Standard Versus Flexible and Navigable Suction Ureteral Access Sheath in Pediatric Flexible Ureterorenoscopy for Renal Stones \u003C 2 cm : A Randomized Controlled Study","FANS-UAS","Inclusion Criteria:\n\n1. Pediatric patients (age ≤ 18 years)\n2. Patients with renal stones less than 2 cm\n3. Indicated for flexible ureterorenoscopy\n4. Fit for general anesthesia\n5. Informed consent obtained from parents or guardians\n\nExclusion Criteria:\n\n1. Stones larger than 2 cm\n2. Active urinary tract infection\n3. Congenital urinary tract anomalies affecting access\n4. Previous ureteral surgery affecting the ureter\n5. Coagulopathy or unfit for surgery","1 Year",{"count":187,"type":22},[57],"This randomized controlled trial aims to compare the efficacy and safety of a Flexible and Navigable Suction Ureteral Access Sheath (FANS) versus a standard ureteral access sheath during flexible ureterorenoscopy (FURS) in pediatric patients with renal stones less than 2 cm. The study will evaluate stone-free rates. operative time. intraoperative parameters. operative and postoperative complication and the need for any auxiliary procedures. Sixty pediatric patients will be randomly allocated into two equal groups and treated at the Urology Department, Tanta University.",[442,443,444],"Pediatric Urolithiasis","Kidney Stone","Nephrolithiasis",[446,447,448,449,450],"Flexible Ureterorenoscopy","Retrograde Intrarenal Surgery","Ureteral Access Sheath","Suction-Assisted Ureteroscopy","Pediatric Urology","2026-07-06",{"date":453,"type":36},"2026-07-08",{"date":455,"type":22},"2026-06-30",{"date":457,"type":22},"2027-06-30",{"name":42,"class":43},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":477,"leadSponsor":479,"locationsCount":44},"100644267","fibrinogen-to-albumin-ratio-as-a-predictor-of-acute-respiratory-distress-syndrome-in-traumatic-brain-injury-100644267","NCT07664358","Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Traumatic Brain Injury","Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Patients With Traumatic Brain Injury: The Prospective, Observational, Multi-center FARDS Study","FARDS","Inclusion Criteria:\n\n* Patients ≥ 18 years admitted to the ICU with traumatic Brain Injury\n* Admission to the ICU within 24 hours of injury.\n* Patients will be expected to remain under hospital care for follow-up\n* Availability of fibrinogen and albumin measurements within the first 24 hours of ICU admission.\n* Informed consent will be obtained from a legally authorized representative.\n\nExclusion Criteria:\n\n* Preexisting advanced chronic liver disease, nephrotic syndrome, or protein-losing enteropathy.\n* Pre-existing ARDS on admission.\n* Recipient of albumin, fibrinogen concentrate, or cryoprecipitate before admission sampling.\n* Use of anticoagulant or fibrinolytic therapy before admission.\n* Active malignancy or severe systemic infection at admission.\n* Direct sever lung injury\n* Pregnancy\n* Refusal of consent",{"count":468,"type":22},350,"this study aims to assess the ability of fibrinogen-to-albumin ratio to predict the development of Acute respiratory distress syndrome in traumatic brain injury patients.",[471,472,473,474],"Fibrinogen","Albumin","ARDS","TBI (Traumatic Brain Injury)",{"date":451,"type":36},{"date":69,"type":36},{"date":478,"type":22},"2027-01-01",{"name":42,"class":43},{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":185,"minAge":19,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":490,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":498,"leadSponsor":500,"locationsCount":44},"100641552","phase-3-intravenous-lidocaine-to-prevent-post-fundal-pressure-headache-during-cesarean-section-100641552","NCT07661758","Intravenous Lidocaine to Prevent Post-Fundal Pressure Headache During Cesarean Section","Pre-emptive Single Intravenous Lidocaine Dose to Prevent Post-Fundal Pressure Headache During Cesarean Section: The LID-HEAD Multi-center Randomized Controlled Trial","LID-HEAD","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* American Society of Anesthesiologists (ASA) Physical Status II\n* Scheduled for elective cesarean section under spinal anesthesia\n\nExclusion Criteria:\n\n* Patients declined to participate in the trial,\n* Patients with history of any type of headache, mental illness, or cerebrovascular diseases\n* Previous epidural insertion for painless labor or any other indications;\n* Patients on opioid or analgesic medications;\n* Those with pregnancy-induced hypertension or diabetic patients,\n* Allergy to lidocaine;\n* Contraindication or failure of spinal anesthesia.",{"count":489,"type":22},680,[26],"This prospective randomized controlled multicenter study will be conducted to evaluate the effects of pre-emptive IV lidocaine dose on the incidence and severity of intraoperative headache that may occur after the extra-abdominal manual uterine fundal pressure in patients undergoing cesarean section under spinal anesthesia.",[493,494,495],"Intravenous Lidocaine","Fundal Pressure","Headache",{"date":451,"type":36},{"date":69,"type":36},{"date":499,"type":22},"2026-11-02",{"name":42,"class":43},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":508,"maxAge":509,"enrollmentInfo":510,"targetDuration":4,"studyType":23,"phases":512,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":521,"leadSponsor":523,"locationsCount":44},"100641205","phase-2-oral-versus-intravenous-magnesium-on-emergence-delirium-100641205","NCT07655817","Oral Versus Intravenous Magnesium on Emergence Delirium","Effect of Oral Versus Intravenous Magnesium on Emergence Delirium in Children Undergoing Adenotonsillectomy: A Two-Center, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* Children aged 4 to 7 years\n* American Society of Anesthesiologist (ASA) Status I or II\n* Planned for an adenotonsillectomy procedure under sevoflurane general anesthesia.\n\nExclusion Criteria:\n\n* Parents declined to participate in the trial\n* Behavioral changes, neurological or psychiatric problems\n* Anticonvulsant or sedative drugs\n* Physical or developmental abnormalities\n* Allergies to magnesium\n* cardiovascular, renal, bone, or gastrointestinal diseases.","4 Years","7 Years",{"count":511,"type":22},360,[25,26],"This prospective randomized controlled study will be conducted to compare the effects of preoperative oral magnesium and intraoperative IV magnesium on the incidence and severity of emergence delirium in children undergoing adenotonsillectomy using sevoflurane anesthesia.",[515,516,517,518],"Magnesium","Emergence Delirium","Children","Adenotonsillectomy",{"date":451,"type":36},{"date":69,"type":36},{"date":522,"type":22},"2026-12-25",{"name":42,"class":43},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":18,"minAge":271,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":533,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":538,"startDateStruct":539,"completionDateStruct":540,"leadSponsor":542,"locationsCount":44},"100641127","phase-3-subcutaneous-calcitonin-in-acute-herpes-zoster-100641127","NCT07655804","Subcutaneous Calcitonin in Acute Herpes Zoster","The Prophylactic Value of Subcutaneous Calcitonin in Acute Herpes Zoster Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* patients aged ≥ 50 years, with acute herpes zoster infection (rash duration \\\u003C 7 days) and moderate to severe pain.\n\nExclusion Criteria:\n\n* Coagulation abnormalities\n* Pre-existing other pain syndrome or psychological disorders.\n* Severe hepatic, cardiovascular, or renal disorders.\n* Allergy to calcitonin.",{"count":532,"type":22},168,[26],"This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.",[536,537,310],"Calcitonin","Subcutaneous",{"date":451,"type":36},{"date":69,"type":36},{"date":541,"type":22},"2027-10-01",{"name":42,"class":43},{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":236,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":23,"phases":552,"briefSummary":553,"conditions":554,"keywords":558,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":44},"100503082","perineural-methylene-blue-infusion-in-lower-limb-amputation-surgery-100503082","NCT05830630","Perineural Methylene Blue Infusion in Lower Limb Amputation Surgery","The Preventive Value of Continuous Perineural Methylene Blue Infusion in Patients Undergoing Lower Limb Amputation Surgery","Inclusion Criteria:\n\n* Patients of both genders, suffering from vascular insufficiency of one or both lower limbs and scheduled for above or below knee amputation under general anesthesia.\n\nExclusion Criteria:\n\n* Patients with a history of allergy to local anesthetics.\n* Patients with allergy to methylene blue.\n* Anticoagulant use or coagulopathy.",{"count":551,"type":22},72,[57],"This prospective randomized controlled study will be conducted to evaluate the analgesic effect of continuous perineural infusion of methylene blue with bupivacaine on acute postoperative pain and to evaluate its preventive role against chronic phantom pain in patients undergoing lower limb amputation surgery",[555,556,557],"Perineural","Methylene Blue","Lower Limb Amputation",[555,559,560],"Methylene blue","Lower limb amputation",{"date":451,"type":36},{"date":563,"type":36},"2023-05-01",{"date":565,"type":22},"2027-11-01",{"name":42,"class":43},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":18,"minAge":574,"maxAge":19,"enrollmentInfo":575,"targetDuration":4,"studyType":23,"phases":576,"briefSummary":577,"conditions":578,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":44},"100644971","microsurgical-single-versus-double-dartos-flap-in-distal-hypospadias-repair-100644971","NCT07676916","Microsurgical Single Versus Double Dartos Flap in Distal Hypospadias Repair","Microsurgical Single Versus Double Dartos Flap in Distal Hypospadias Repair: A Prospective Randomized Trial","Inclusion Criteria:\n\n* Male patients diagnosed with Distal Hypospadias.\n* Age: From 6 months to 18 years.\n* Primary cases.\n* Uretheral Plate\\>8mm.\n* Glanular width≥14mm.\n\nExclusion Criteria:\n\n* Coronal and glanular hypospadias.\n* Severe chordee.\n* Associated disorders of sexual development.\n* Un-controlled bleeding disorders.","6 Months",{"count":147,"type":22},[57],"This study aims to compare the surgical and functional outcomes of microsurgical single dartos flap versus double dartos flap in distal hypospadias repair.",[579,580,581,582],"Microsurgical","Single Dartos Flap","Double Dartos Flap","Distal Hypospadias Repair","2026-06-24",{"date":455,"type":36},{"date":586,"type":36},"2026-05-16",{"date":588,"type":22},"2027-04-01",{"name":42,"class":43},{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":18,"minAge":271,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":23,"phases":597,"briefSummary":598,"conditions":599,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":606,"leadSponsor":608,"locationsCount":44},"100643880","intraarticular-injection-of-botox-and-hyaluronic-acid-in-knee-osteoarthritis-100643880","NCT07666347","Intraarticular Injection of Botox and Hyaluronic Acid in Knee Osteoarthritis","Inclusion Criteria:\n\n* Age ≥ 50 years.\n* Both genders.\n* Chronic knee osteoarthritis (KOA) according to American College of Rheumatology criteria for the diagnosis of knee osteoarthritis.\n* Third or fourth grade Kellgren and Lawrence system for classification of osteoarthritis based on radiological data, it is a common method of classifying the severity of osteoarthritis (OA) using five grades according to the following sites and projections.\n\nExclusion Criteria:\n\n* History of intra-articular injection within the last 6 months,\n* History of surgery on the knee joint or major trauma to the lower limb causing fracture.\n* Body mass index (BMI) more than 40 kg\u002Fm2.\n* Medical conditions affecting the joint or lower extremity function such as severe osteoporosis, rheumatoid arthritis, collagen vascular diseases, and gout.\n* Diabetic patient.\n* Any contraindication to intra-articular injections for instance immunodeficiency, coagulation defect or anticoagulation therapy taking or skin infection at the site of injection.\n* Hypersensitivity to Botulinum toxin or hyaluronic acid.",{"count":21,"type":22},[57],"This study aims to compare the efficacy of intra-articular injection of Botulinum toxin and hyaluronic acid on pain in knee osteoarthritis.",[600,601,602,171],"Intraarticular Injection","Botox","Hyaluronic Acid",{"date":604,"type":36},"2026-06-25",{"date":583,"type":36},{"date":607,"type":22},"2026-12-01",{"name":42,"class":43},""]